We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+45.58%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$481M
AUM Growth
-$463M
Cap. Flow
-$640M
Cap. Flow %
-133.1%
Top 10 Hldgs %
88.89%
Holding
20
New
3
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$10.4M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$9.27M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.58M
4
QURE icon
uniQure
QURE
+$2.99M
5
GMAB icon
Genmab
GMAB
+$1.5M

Top Sells

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$10.9M
2
ARWR icon
Arrowhead Research
ARWR
+$10.1M
3
SPRO icon
Spero Therapeutics
SPRO
+$8.81M
4
ANAB icon
AnaptysBio
ANAB
+$6.36M
5
ACIU icon
AC Immune
ACIU
+$2.26M

Sector Composition

Rank Sector Weight
1 Healthcare 63.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRO icon
1
Spero Therapeutics
SPRO
$73M
$76.2M 15.85%
3,932,209
-564,933
-13% -$8.81M
IBB icon
2
PUT
iShares Biotechnology ETF
IBB
$9.71B
$75.7M 15.73%
+500,000
New +$71.5M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$70.4M 14.63%
500,000
-3,500,000
-88% -$448M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$42.6M 8.86%
380,012
-5,715
-1% -$602K
NGM
5
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$30.5M 6.33%
1,005,534
-12,800
-1% -$280K
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$29.9M 6.21%
1,355,392
-19,384
-1% -$427K
ARWR icon
7
Arrowhead Research
ARWR
$12.4B
$28.1M 5.84%
365,926
-157,489
-30% -$10.1M
ANAB icon
8
AnaptysBio
ANAB
$1.68B
$26.1M 5.43%
1,215,958
-261,694
-18% -$6.36M
QURE icon
9
uniQure
QURE
$3.22B
$25.4M 5.27%
702,050
+70,990
+11% +$2.99M
RGNX icon
10
Regenxbio
RGNX
$708M
$22.8M 4.75%
503,444
-7,316
-1% -$256K
DNTH icon
11
Dianthus Therapeutics
DNTH
$6.09B
$17.8M 3.69%
141,651
+81,737
+136% +$9.27M
AMYT
12
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$11.3M 2.35%
+800,000
New +$10.4M
PVLA
13
Palvella Therapeutics
PVLA
$2.27B
$9.19M 1.91%
45,944
– –
LKFT
14
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$6.93M 1.44%
69,989
+37,455
+115% +$4.58M
ARGX icon
15
argenx
ARGX
$54.1B
$3.73M 0.78%
12,700
+5,200
+69% +$1.43M
GMAB icon
16
Genmab
GMAB
$19.5B
$3.66M 0.76%
90,000
+40,000
+80% +$1.5M
FDMT icon
17
4D Molecular Therapeutics
FDMT
$562M
$829K 0.17%
+20,000
New +$826K
ACIU icon
18
AC Immune
ACIU
$240M
– –
-463,575
Closed -$2.26M
IWM icon
19
PUT
iShares Russell 2000 ETF
IWM
$81.9B
– –
-1,700,000
Closed -$255M
PRQR icon
20
ProQR Therapeutics
PRQR
$265M
– –
-2,281,966
Closed -$10.9M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Aquilo Capital Management held 20 positions worth $481M, down 49% from $945M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Aquilo Capital Management withdrew a net $640M in Q4 2020, closing 3 positions and reducing 8 holdings. Its most notable exit was ProQR Therapeutics, an estimated $10.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 23% a quarter earlier.

Against the trend, Aquilo Capital Management opened a new position in Amryt Pharma plc American Depositary Shares worth $11.3M.

  • Aquilo Capital Management's largest Q4 2020 buy was Amryt Pharma plc American Depositary Shares: 800,000 shares worth $11.3M.
  • Aquilo Capital Management added most to Dianthus Therapeutics in Q4 2020, an estimated $9.27M increase.
  • Aquilo Capital Management's biggest Q4 2020 reduction was Arrowhead Research, cutting an estimated $10.1M.
  • Aquilo Capital Management fully exited ProQR Therapeutics in Q4 2020, selling an estimated $10.9M.
  • Aquilo Capital Management's ten largest holdings make up 89% of its $481M portfolio in Q4 2020.
  • Aquilo Capital Management opened 3 new positions and closed 3 in Q4 2020.
  • Aquilo Capital Management's portfolio value fell 49% quarter-over-quarter to $481M.

Based on Aquilo Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.